In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines. Through its partnerships, the Genetic Medicines division is ...

Drug developed by Northwestern scientists Fatal brain cancer has no current cure Drug is revolutionary new class of drugs applicable to other neurological diseases CHICAGO --- An early clinical trial ...

Chinese RNA drug developer Ribo has launched a Hong Kong IPO, positioning its lead siRNA candidate for thrombotic diseases as ...

Anti-nucleolin DNA aptamer, iSN04, inhibits angiogenesis. Mouse aortic rings embedded in collagen gel were cultured with or without 30 µM iSN04 for 6 days. Neovascular sprouting, a model of ...

An announcement from CF PharmTech. Inc. Class H ( ($HK:2652) ) is now available. CF PharmTech announced that its company-led project to develop ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...

In the past decade, nucleic-acid-based drugs have become firmly established as a therapeutic modality. Drugs in two classes have now reached the market for multiple diseases—antisense oligonucleotides ...

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." (*2) As a new ...